Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

This study is about finding a new and gentle way to help people with Parkinson's disease who also have what are called 'impulse control disorders' (ICDs). These are behaviours like compulsive gambling, shopping, eating, or hypersexuality, which can be very distressing and difficult to manage. While there are some ways doctors try to help with ICDs now, they often come with their own challenges, such as making Parkinson's symptoms worse or having other serious side effects. This means we don't currently have a really good, safe, and effective treatment for these issues.

That's where this new research comes in. It's looking at a medication called pimavanserin. This medicine has already been approved in the United States to treat hallucinations and delusions in people with Parkinson's disease, showing it can be helpful and generally safe for this group. Scientists believe that specific brain chemicals, particularly something called serotonin, play a big role in both Parkinson's and impulse control disorders. Since pimavanserin works by affecting how serotonin behaves in the brain, it's thought it might also be able to reduce these impulsive behaviours.

So, the main goal of this study is to carefully check if pimavanserin can help reduce impulse control disorders in people with Parkinson's disease, and to make sure it's safe to use. If successful, this could offer a much-needed new treatment option, making a big difference to the daily lives of people living with both Parkinson's and ICDs. The researchers want to understand if this medicine can improve quality of life without causing new problems.